Actively Recruiting

Phase 1
Age: 2Years +
MALE
NCT07433621

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Led by Children's Hospital Medical Center, Cincinnati · Updated on 2026-03-27

12

Participants Needed

1

Research Sites

170 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of the study is to evaluate safety and tolerability of oral quercetin in reducing inflammation in male patients with XIAP deficiency. Quercetin is a naturally occurring antioxidant that has many properties including the ability to decrease inflammation in other diseases.

CONDITIONS

Official Title

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Who Can Participate

Age: 2Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients
  • Diagnosis of XIAP deficiency
  • Patients 62 years of age
  • Serum IL-18 62600 pg/mL (approximately 25% above the lab-defined upper limit of normal of 477 pg/mL)
  • Able to take enteral medication
Not Eligible

You will not qualify if you...

  • Renal failure requiring dialysis
  • Total bilirubin >3 mg/dl and/or SGPT >300 at time of enrollment
  • Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons
  • Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons
  • Patients who are at risk of pregnancy or fathering a child and are unable to use acceptable methods of birth control during the length of the study
  • Patients who have received quercetin or any over the counter anti-oxidant supplementation within last 1 month
  • Patients with unstable disease status or other medical issues requiring hospitalization or rapid escalation of medical care
  • Participating in another therapeutic study for XIAP deficiency

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

Loading map...

Research Team

K

Kelly McIntosh

CONTACT

R

Richard Cooper

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency | DecenTrialz